CTOs on the Move

Ascend Healthcare

www.ascendhc.com

 
Ascend Healthcare is a residential treatment facility for teens struggling with mental health and addiction issues. They provide evidence-based therapies, experiential therapies, and a unique clinical approach to help their clients. Their focus on fami...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ascendhc.com
  • 11515, West Washington Boulevard
    Los Angeles, CA USA 90066
  • Phone: 310.388.3713

Executives

Name Title Contact Details

Similar Companies

Voorhees Pediatric Facility

Voorhees Pediatric Facility is a Voorhees, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Flugen

FluGen is driving the development of a universal flu vaccine to advance human health.

Arizona Oncology

Premier Cancer Treatment throughout Arizona - Phoenix - Tucson - Chemotherapy, Radiation Therapy, Gynecologic, Clinical Research

NetMD Business

NetMD Business is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bionor Pharma

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.